William Blair Has Pessimistic Outlook of Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair dropped their Q1 2025 earnings per share estimates for Hologic in a report issued on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will post earnings of $1.00 per share for the quarter, down from their prior estimate of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s FY2026 earnings at $4.62 EPS.

Other equities research analysts have also recently issued research reports about the company. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Stephens restated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $77.54 on Wednesday. The business’s 50 day moving average price is $80.77 and its two-hundred day moving average price is $78.22. The company has a market cap of $18.01 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic has a twelve month low of $67.59 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.89 earnings per share.

Institutional Investors Weigh In On Hologic

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC bought a new stake in Hologic during the third quarter worth $25,000. Innealta Capital LLC bought a new stake in Hologic during the second quarter worth $25,000. iA Global Asset Management Inc. bought a new stake in Hologic during the first quarter worth $37,000. First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares in the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in shares of Hologic during the second quarter worth $37,000. 94.73% of the stock is currently owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.